Research graph
References from The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: A network meta-analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland
10.1016/j.msard.2020.101980 · 2020 · External reference
Unresolved reference
2019 · External reference
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study
10.1212/wnl.0000000000005516 · 2018 · External reference
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells
10.1084/jem.20111675 · 2012 · External reference
Experience with rituximab therapy in a real-life sample of multiple sclerosis patients
10.1007/s10072-020-04434-1 · 2020 · External reference
Unresolved reference
2019 · External reference
Visualizing assumptions and results in network meta-analysis: the network graphs package
10.1177/1536867x1501500402 · 2015 · External reference
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
10.1016/s0140-6736(12)61768-1 · 2012 · External reference
Role of B cells in multiple sclerosis and related disorders
10.1002/ana.25927 · 2021 · External reference
Immunopathogenesis
2020 · External reference
Rituximab combination therapy in relapsing multiple sclerosis
10.1177/1756285612461165 · 2012 · External reference
The cerebrospinal fluid in multiple sclerosis
10.3389/fimmu.2019.00726 · 2019 · External reference
Immunopathology of multiple sclerosis
10.1038/nri3871 · 2015 · External reference
Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis
10.1016/j.msard.2016.06.001 · 2016 · External reference
Unresolved reference
External reference
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
10.1177/1352458520918375 · 2021 · External reference
Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy
2017 · External reference
10.1201/9781003107347
10.1201/9781003107347 · External reference
Ofatumumab versus teriflunomide in multiple sclerosis
10.1056/nejmoa1917246 · 2020 · External reference
Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
10.1056/nejmoa1601277 · 2017 · External reference
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
10.1056/nejmoa0706383 · 2008 · External reference
Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
10.1002/jrsm.1044 · 2012 · External reference
Unresolved reference
2019 · External reference
Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis
10.1212/wnl.0000000000006916 · 2019 · External reference
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations
10.7326/m14-2385 · 2015 · External reference
Rituximab treatment for multiple sclerosis
10.1177/1352458519858604 · 2020 · External reference
Assessing changes in relapse rates in multiple sclerosis
10.1177/1352458510379246 · 2010 · External reference
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
10.1016/s0140-6736(11)61649-8 · 2011 · External reference
Neuroinflammation, neurodegeneration and regeneration in multiple sclerosis: intercorrelated manifestations of the immune response
10.4103/1673-5374.194804 · 2016 · External reference
Th17 cells in autoimmune inflammation and demyelination in the central nervous system
2013 · External reference
Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges
10.1177/1756285612474333 · 2013 · External reference
Unresolved reference
2020 · External reference
Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination
10.1186/s40478-017-0428-6 · 2017 · External reference
Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis
10.1007/s00415-019-09395-w · 2020 · External reference
Disease-modifying therapies for relapsing–remitting multiple sclerosis: a network meta-analysis
10.1007/s40263-018-0541-5 · 2018 · External reference
Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis
10.1016/j.msard.2018.12.040 · 2019 · External reference
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial
10.1212/wnl.0b013e3181e24373 · 2010 · External reference
The applications of anti-CD20 antibodies to treat various B cells disorders
10.1016/j.biopha.2018.11.121 · 2019 · External reference
Ranking treatments in frequentist network meta-analysis works without resampling methods
10.1186/s12874-015-0060-8 · 2015 · External reference
Evaluating the quality of evidence from a network meta-analysis
10.1371/journal.pone.0099682 · 2014 · External reference
Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis
10.2217/cer-2020-0122 · 2020 · External reference
10.1002/9781119536604.ch14
10.1002/9781119536604.ch14 · External reference
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study
10.1212/wnl.0000000000000125 · 2014 · External reference
Time to first relapse as an endpoint in multiple sclerosis clinical trials
10.1177/1352458512457841 · 2013 · External reference
RoB 2: a revised tool for assessing risk of bias in randomised trials
10.1136/bmj.l4898 · 2019 · External reference
Unresolved reference
External reference
Persistence of intrathecal oligoclonal B cells and IgG in multiple sclerosis
10.1016/j.jneuroim.2019.576966 · 2019 · External reference
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
2015 · External reference
Unresolved reference
External reference
The use of (network) meta-analysis in clinical oncology
10.3389/fonc.2019.00822 · 2019 · External reference
Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
10.1016/s1474-4422(18)30443-5 · 2019 · External reference
Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study
10.1155/2018/9084759 · 2018 · External reference
